938 related articles for article (PubMed ID: 27852009)
1. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
Chistiakov DA; Orekhov AN; Bobryshev YV
Int J Cardiol; 2017 Jan; 227():66-82. PubMed ID: 27852009
[TBL] [Abstract][Full Text] [Related]
2. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic-related therapeutic challenges in cardiovascular disease.
Schiano C; Vietri MT; Grimaldi V; Picascia A; De Pascale MR; Napoli C
Trends Pharmacol Sci; 2015 Apr; 36(4):226-35. PubMed ID: 25758254
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Regulatory Mechanisms Induced by Resveratrol.
Fernandes GFS; Silva GDB; Pavan AR; Chiba DE; Chin CM; Dos Santos JL
Nutrients; 2017 Nov; 9(11):. PubMed ID: 29104258
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy.
Myasoedova VA; Sukhorukov V; Grechko AV; Zhang D; Romanenko E; Orekhov V; Orekhov AN
Curr Pharm Des; 2019; 25(6):635-641. PubMed ID: 30950345
[TBL] [Abstract][Full Text] [Related]
6. Targeting epigenetic DNA and histone modifications to treat kidney disease.
Fontecha-Barriuso M; Martin-Sanchez D; Ruiz-Andres O; Poveda J; Sanchez-Niño MD; Valiño-Rivas L; Ruiz-Ortega M; Ortiz A; Sanz AB
Nephrol Dial Transplant; 2018 Nov; 33(11):1875-1886. PubMed ID: 29534238
[TBL] [Abstract][Full Text] [Related]
7. Epigenetics and cancer treatment.
Kristensen LS; Nielsen HM; Hansen LL
Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
9. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic regulation of gene expression as an anticancer drug target.
Ferguson LR; Tatham AL; Lin Z; Denny WA
Curr Cancer Drug Targets; 2011 Feb; 11(2):199-212. PubMed ID: 21158714
[TBL] [Abstract][Full Text] [Related]
11. The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review.
Vahid F; Zand H; Nosrat-Mirshekarlou E; Najafi R; Hekmatdoost A
Gene; 2015 May; 562(1):8-15. PubMed ID: 25701602
[TBL] [Abstract][Full Text] [Related]
12. An overview of epigenetic agents and natural nutrition products targeting DNA methyltransferase, histone deacetylases and microRNAs.
Huang D; Cui L; Ahmed S; Zainab F; Wu Q; Wang X; Yuan Z
Food Chem Toxicol; 2019 Jan; 123():574-594. PubMed ID: 30408543
[TBL] [Abstract][Full Text] [Related]
13. Impact of epigenetics in the management of cardiovascular disease: a review.
Cao Y; Lu L; Liu M; Li XC; Sun RR; Zheng Y; Zhang PY
Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):3097-104. PubMed ID: 25392111
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.
Vendetti FP; Rudin CM
Expert Opin Biol Ther; 2013 Sep; 13(9):1273-85. PubMed ID: 23859704
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of epigenetic therapy in cancer.
Hellebrekers DM; Griffioen AW; van Engeland M
Biochim Biophys Acta; 2007 Jan; 1775(1):76-91. PubMed ID: 16930846
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors.
Katarzyna R; Lucyna B
J Cancer Res Ther; 2019; 15(5):961-970. PubMed ID: 31603095
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic-based therapies in cancer: progress to date.
Song SH; Han SW; Bang YJ
Drugs; 2011 Dec; 71(18):2391-403. PubMed ID: 22141383
[TBL] [Abstract][Full Text] [Related]
18. [DNA methyltransferase inhibitors * histone deacetylase inhibitors].
Kikuchi J; Furukawa Y
Nihon Rinsho; 2014 Jun; 72(6):1136-42. PubMed ID: 25016817
[TBL] [Abstract][Full Text] [Related]
19. Genistein Induces Alterations of Epigenetic Modulatory Signatures in Human Cervical Cancer Cells.
Sundaram MK; Ansari MZ; Al Mutery A; Ashraf M; Nasab R; Rai S; Rais N; Hussain A
Anticancer Agents Med Chem; 2018; 18(3):412-421. PubMed ID: 28925878
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer.
Oh S; Ko JY; Oh C; Yoo KH
Adv Exp Med Biol; 2017; 1026():287-313. PubMed ID: 29282690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
